Biotechnology Companies in the News – October 2011

Editor’s Note: The home page of the BioNJ website provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to send their news releases to BioNJ via email.

October 14

Columbia Laboratories to Present October 21st at NewsMakers in the Biotech Industry Conference

Bristol-Myers Squibb Foundation Announces Six New Grants to Bridge Gaps in Cancer Awareness, Prevention and Care in Central and Eastern Europe

Celldex Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference

October 13

Cyclacel Announces Data Safety Monitoring Board Recommendation To Continue The Seamless Phase 3 Trial Of Sapacitabine

Merck’s ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Virological and Immunological Efficacy Versus the Efavirenz Regimen at 192 Weeks of Treatment in Previously Untreated Adults with HIV-1

Nominations Sought for First SAFE-BioPharma Digital Identity Awards

Derma Sciences Launches MEDIHONEY® Gel at the Fall Symposium on Advanced Wound Care 2011

EKR Therapeutics Announces Senior Management Change

Aegerion Pharmaceuticals to Announce Third-Quarter 2011 Financial Results on Thursday, October 27

October 12

Celgene Corporation to Announce Third Quarter 2011 Results on October 27, 2011

STENTYS Self-Apposing Stents in “Perfect Apposition to Vessels” After Treating Patients with Heart Attacks

The Medicines Company to Announce Third Quarter 2011 Financial Results on Wednesday, October 26, 2011

October 11

Immunomedics Awarded U.S. Patent For Cytokine-Antibody Complexes

Soligenix Announces Formation of Pediatric Crohn’s Disease Medical Advisory Board

Bristol-Myers Squibb Foundation Announces Collaboration with World Health Organization’s Stop TB Department to Strengthen Community Based Care of Tuberculosis Including HIV Co-Infection in Five African Countries

Advaxis Granted Pre-IND Meeting with FDA for ADXS-HER2, an Immunotherapy for HER2 Expressing Cancers

Rutgers Launches $1M Fund to Encourage Disruptive Innovation

October 10

Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C

October 7

CorMedix to Host Conference Call on Recent Developments

October 6

Unigene and Nordic Bioscience Combine Industry Leading Capabilities to Advance Unigene’s Proprietary Peptides through Phase 2 Proof-of-Concept for the Treatment of Type 2 Diabetes, Osteoarthritis and Osteoporosis

Unigene’s Leading Peptide Development Expertise Endorsed with Strategic Equity Investment of Up To $6 Million by Industry Legend Dr. Claus Christiansen

Unigene to Host Live Conference Call and Webcast to Discuss Collaboration with Nordic Bioscience and Formation of Joint Development Vehicle

Merck Announces Retirement of Chairman and Former CEO Richard T. Clark

Rutgers-Affiliated Startup Gets Funding for Breast Cancer Analysis Tools

October 5

Alliance Life Sciences Releases White Paper Aimed at Process Integration in Reorganizations, Mergers and Acquisitions

October 4

Merck Adds New Medication Adherence Resources to Consumer Web Site

Antares Pharma Granted New U.S. Patent Covering VIBEX™ Injector Technology

FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor

October 3

The Medicines Company Launches New Formulation of Cleviprex(R) (Clevidipine) Injectable Emulsion

The Medicines Company Settles Angiomax(R) (Bivalirudin) Patent Litigations With Teva

Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX® (alendronate sodium)

September 30

Roche Adds to Nutley Campus with Manufacturing Hub

Merck to Hold Third-Quarter 2011 Sales and Earnings Conference Call on October 28

Merck Announces New Data Analyses for VICTRELIS™ (boceprevir) will be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting

Bristol-Myers Squibb to Present New Data Demonstrating Company’s Leadership in Liver Disease at The Liver Meeting® / AASLD Annual Meeting

CorMedix Announces Strategic Changes Primary Focus on European Approval of Neutrolin® Executive Management Changes

September 29

CorMedix Announces FDA Designation for Neutrolin (CRMD003)

Durata Therapeutics Initiates Enrollment in DISCOVER-2, Second Phase 3 Study of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Sanofi US Launches healthFORWARD 2.0

September 28

Merck Names Cuong Viet Do as Chief Strategy Officer

Bauer LLC Demonstrates an Improved Approach to Graph Cannulation for Dialysis Patients with Grafts

September 27

MicroDose Therapeutx Begins Phase 1 Trialof MDT-637 for Treatment of RespiratorySyncytial Virus

September 26

SwabCap to Be Focus of Four Presentations at AVA Conference

NPS Pharmaceuticals Appoints Eric Pauwels as Chief Commercial Officer

Contract Research Organization DSP Clinical Research Achieves 1,266 Ranking on Inc. 500/5000 List; Fourth Consecutive Year DSP Earns Recognition

New Data Analyses from Lorcaserin Phase 3 Clinical Trials to be Presented at Obesity 2011

September 23

Helsinn Group and Eisai Inc. Announce Start of Phase III Clinical Program of Oral Fixed-Dose Combination of Netupitant/Palonosetron (300 mg/0.50 mg) for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)

Celgene Regulatory Update on REVLIMID(R)

Walgreens Take Care Health Systems and Sanofi US Open On-site Medical Center and Pharmacy

September 22

Columbia Laboratories Extends Stockholder Rights Plan to Preserve Use of Net Operating Losses under Section 382

Bristol-Myers Squibb and Ambrx Announce Collaboration for Novel Biologics Programs in Diabetes and Heart Failure

Enzon Announces Reduction in Force to Align Operations with Research and Development Activities

Immunomedics Announces Partial Clinical Hold on Clivatuzumab Tetraxetan Clinical
Trial

Cyclacel Pharmaceuticals Receives Deficiency Notice from NASDAQ Global Select Market

The Medicines Company to Participate in the Jefferies 2011 Global Healthcare Conference in London

September 21

Unigene Divests Non-Core Asset and Focuses Resources on High Valuation Drug Development and Peptide Drug Delivery Opportunities – Assigns Site Directed Bone Growth Patent Portfolio to Leading Researcher

Merck Chief Medical Officer to Discuss the Future of Innovation at Biotech 2011

Celgene Corporation to Present at JMP Securities Healthcare Conference 2011

September 20

First Patients Enrolled in the U.S. OPEN Clinical Trial of the FlexStent® Femoropopliteal SE Stent System

Bristol-Myers Squibb and Ono Enter into Strategic Agreement for Anti-PD-1 Antibody, BMS-936558/ONO-4538, and ORENCIA® (abatacept)

Merck Joins Global Fight to Help Save Women’s Lives During Pregnancy and Childbirth President and CEO Ken Frazier Announces 10-Year, $500 Million Mobilization

Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer Andrew I. Koven Also Joins Neurologix as Company President and Chief Administrative Officer

Bristol-Myers Squibb Announces Dividend

September 19

Unigene’s Industry Leading, Proprietary Oral Delivery and Recombinant Manufacturing Technology Platforms are Further Validated with Positive Phase 3 Safety and Efficacy Data for OSTORA(TM)

Rutgers Focuses on Business Partnerships

Aestus Therapeutics and Prosidion Ltd Sign License Agreement for Novel Chronic Pain Therapeutic

ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies

Merck’s ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Efficacy and Tolerability in an Observational Trial in a Diverse Population of Adults with HIV-1 Regardless of Gender or Race

September 16

NPS Pharmaceuticals Highlights Hypoparathyroidism Data to Be Presented at Annual Meeting of American Society for Bone and Mineral Research

ONGLYZA™ (saxagliptin) When Added to Insulin in Adults with Type 2 Diabetes Maintained Reductions in Blood Sugar Levels (HbA1c) Over 52 Weeks in Investigational Study Extension